Climb Bio, Inc. (CLYM)
NASDAQ: CLYM · Real-Time Price · USD
1.270
+0.030 (2.42%)
May 13, 2025, 4:00 PM - Market closed
Climb Bio Employees
As of December 31, 2024, Climb Bio had 18 total employees, including 17 full-time and 1 part-time employees. The number of employees increased by 7 or 63.64% compared to the previous year.
Employees
18
Change (1Y)
7
Growth (1Y)
63.64%
Revenue / Employee
n/a
Profits / Employee
-$4,105,389
Market Cap
85.82M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 18 | 7 | 63.64% |
| Dec 31, 2023 | 11 | -32 | -74.42% |
| Dec 31, 2022 | 43 | 12 | 38.71% |
| Dec 31, 2021 | 31 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CLYM News
- 6 weeks ago - Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors - GlobeNewsWire
- 6 weeks ago - Climb Bio to Present at the 24th Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 7 weeks ago - Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 2 months ago - Climb Bio to Present at Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Climb Bio Appoints Perrin Wilson, Ph.D., as Chief Business Officer - GlobeNewsWire
- 3 months ago - Climb Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 4 months ago - Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy - GlobeNewsWire
- 5 months ago - Climb Bio to be Added to the Nasdaq Biotechnology Index - GlobeNewsWire